Has Mikki Barker received payments from drug or device companies?

Yes. Drug and device makers reported $5,355 in general payments to Mikki Barker across 215 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Mikki Barker did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Mikki Barker come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Mikki Barker

Psychiatry · Fairbanks, AKNPI 1639240740

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.1% of the total across 215 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by AbbVie at 31.8% of the total. Reporting peaked in 2024 at $1,974 and has fallen 61.2% since, to $765 in 2025. Among psychiatry clinicians in AK with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$5,355in general payments, 2019–2025

Across 215 payments — averaging $24.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$2K
Johnson & Johnson$844
Alkermes, Inc.$785
Neurocrine Biosciences, Inc.$685
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$459
Teva Pharmaceuticals USA, Inc.$335
plus $547 from 10 others

What the payments were for

Food & beverage$5,19997%
Education$1563%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie(2 entities)	99	$1,701
Johnson & Johnson	26	$844
Alkermes, Inc.	28	$785
Neurocrine Biosciences, Inc.	11	$685
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)	17	$459
Teva Pharmaceuticals USA, Inc.	9	$335
Otsuka America Pharmaceutical, Inc.	9	$232
Lundbeck LLC	3	$64
E.r. Squibb & Sons, L.L.C.	2	$53
Sage Therapeutics, LLC	2	$44
Takeda Pharmaceuticals U.S.A., Inc.	2	$39
Vanda Pharmaceuticals Inc.	2	$37
Supernus Pharmaceuticals, Inc.	2	$31
Shire North American Group Inc	1	$19
Almatica Pharma LLC	1	$15
Tris Pharma Inc	1	$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,355 in reported general payments places this provider in the 95th percentile of 81 psychiatry providers in Alaska.

See all psychiatry providers in Alaska →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
IngrezzaValbenazine Tosylate	11	$84,815
RexultiBrexpiprazole	49	$79,955
Abilify MaintenaAripiprazole	19	$41,746
VraylarCariprazine Hcl	22	$31,103
Aripiprazole	41	$3,745
Sertraline Hcl	28	$1,659
Divalproex Sodium ErDivalproex Sodium	25	$1,632
Trazodone Hcl	120	$1,479
Quetiapine Fumarate	76	$1,231
Gabapentin	91	$989
Hydroxyzine Hcl	39	$864
Prazosin Hcl	46	$840
Divalproex Sodium	26	$837
Duloxetine Hcl	40	$622
Olanzapine	16	$571

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena	$232	$121,70168 claims
Neurocrine Biosciences, Inc.Ingrezza	$685	$84,81511 claims
AbbVieVraylar	$1,701	$31,10322 claims
Almatica Pharma LLCSertraline Hcl	$15	$1,65928 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 81 psychiatry providers in Alaska.

Other psychiatry in Fairbanks

Anthony BlanfordFairbanks$303
Sasha EricksenFairbanks$62
Daniel RohlfFairbanks$27
Alex OrtenAnchorage$116K
Howard DetwilerAnchorage$5K
Michelle MoyerSoldotna$3K
Sean CostelloSoldotna$1K
Cleve ShireyAnchorage$846
Ryah McKinleyPalmer$801
David SamsonAnchorage$665

See the full list for Alaska →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →